Vivus, a publicly traded Mountain View drug developer focused on obesity and sexual health, received $33.6 million in private equity financing, after the company announced deepening losses.

Caxton Advantage Life Sciences Fund led the financing. Also participating were Franklin Templeton Investments, Quogue Capital LLC, Euclid SR Partners and OrbiMed Advisors.

The news was first reported by VentureWire this morning (sub required).

There is a statement at the Vivus web site.